Not Found
On Demand

Growing Up Isn’t for the Faint of Bladder: Urologic Concerns in Geriatric Patients, When the Stakes Are High & Emotions Run Strong: Ethical Dilemmas at the End of Life & Special Aspects of Geriatric Pharmacology


Total Credits: 1 including 3 AOA Category 1-A Credit(s)

Average Rating:
Not yet rated
State Associations:
WOMA - Washington
Faculty:
Matthew A. Uhlmann, MD, MBA, MD, MBA |  Andrea Chatburn, DO, MA, HEC-C |  William Elliott, M.D. Ph.D.
Duration:
3 Hours 3 Minutes
Expiration:
Never expires.


Description

Growing Up isn't for the Faint of Bladder: Urologic Concerns in Geriatric Patients-Matthew Uhlman, MD

A common adage in Urology is, "It's not if you'll see us, it's when". As patient's get older, this seems to hold more and more true. As the population continues to grow up, more patients over the age of 65 are presenting with Urologic problems. While many treatment options exist for such patients, special considerations must be given to geriatric patients. This presentation will help primary care physicians identify age specific treatment options for some of the most common Urologic issues facing their geriatric patients. A common adage in Urology is, "It's not if you'll see us, it's when". As patient's get older, this seems to hold more and more true. As the population continues to grow up, more patients over the age of 65 are presenting with Urologic problems. While many treatment options exist for such patients, special considerations must be given to geriatric patients. This presentation will help primary care physicians identify age specific treatment options for some of the most common Urologic issues facing their geriatric patients. 


When the Stakes are High & Emotions Run Strong: Ethical Dilemmas at the End of Life-Andrea Chatburn, DO

Join Palliative Care expert Chatburn for a lighthearted, entertaining journey through what might otherwise be a heavy topic: end of life. POLST forms, Code Status, and Conversation Tools, oh my!  


Special Aspects of Geriatric Pharmacology-William Elliott, MD, PhD

Older (or perhaps more properly, “mature”) individuals are special for many reasons, and drug prescribing for them should also be special. They are much more likely than younger, healthier patients to suffer adverse drug experiences. Some of this can be ascribed to the natural decline in real function that occurs with age (which is often not accounted for by prescribers); much of the rest can be attributed to a normal decline in respiratory and cardiac function, the greater probability of other diseases, polypharmacy directed to these other diseases, and changes in sensitivity of the CNS to many drugs that act there (e.g., opioids). Many managed care organizations search for prescriptions that are deemed “inappropriate” for use in older people, and use this as an inverse quality of care indicator. We will review the classes of drugs (and in some cases, name names) on most of these lists, and highlight the five drugs currently FDA-approved for the treatment of Alzheimer’s disease (which is now largely a disease of older people).

 

The Washington Osteopathic Medical Association is accredited by the American Osteopathic Association as a Category 1 CME Sponsor.

Faculty

Matthew A. Uhlmann, MD, MBA, MD, MBA's Profile

Matthew A. Uhlmann, MD, MBA, MD, MBA Related seminars and products: 2


Matt Uhlman is second generation Urologist practicing in his hometown of Yakima, Washington. His training took him to UW, Duke, Iowa and now back home. He loves spending time with his best half, Missa, and their three boys, traveling, food blogging, spending time with friends and exploring the Northwest.  My goal for this presentation is for the audience to gain a better understanding of ways to effectively treat and combat the issues that will face your geriatric patients. 

CV

Faculty Disclosure


Andrea Chatburn, DO, MA, HEC-C's Profile

Andrea Chatburn, DO, MA, HEC-C Related seminars and products: 1


Dr. Andi Chatburn is a Palliative Care physician in Spokane, Washington and serves as the Regional Director for Ethics for Providence St. Joseph Health in Washington and Montana.
Her interests include navigating care for those on the margins of life, due to serious illness or social determinants of health. Chatburn values time spent “standing in the gap” of uncertainty in clinical questions ranging from beginning to the end of life. This promotes curiosity and relationship while exploring questions of ‘how we ought to be with one another in community’ as we seek to address the challenges of promoting health for a better world.
 

Andi enjoys traveling with her husband John and exploring the Pacific Northwest through hiking and XC skiing with her two big dogs, Fairbanks and Moxie. During the global pandemic she has rediscovered her love of gardening and preserving the harvest and is currently learning how to make cheese.

CV


William Elliott, M.D. Ph.D.'s Profile

William Elliott, M.D. Ph.D. Related seminars and products: 3

Chair, Department of Biomedical Sciences

Pacific NW University of Health Sciences College of Osteopathic Medicine


William J. Elliott, M.D., Ph.D. is Professor of Preventive Medicine,  Internal Medicine, and Pharmacology, Chief of the Division of Pharmacology, and Chair of The Department of Biomedical Sciences at the Pacific Northwest University of Health Sciences in Yakima, WA. After receiving the B.S. (summa cum laude) from the University of Notre Dame, he earned the M.D. and Ph.D. (in Bio-Organic Chemistry) from the University of Chicago. He trained in Internal Medicine and Pharmacology at Barnes Hospital and Washington University—St. Louis, and served as a member of the faculty of the University of Chicago from 1985-92. During the next 17 years at RUSH Medical College, he practiced, taught and did research on cardiovascular clinical pharmacology, focusing on epidemiologic studies of risk factors (including diagonal earlobe creases), laboratory investigations, federally-funded cooperative clinical trials, and many industry-supported endeavors, serving as principal investigator for about 200 clinical trials of new drugs.  Dr. Elliott holds Board Certification in both Internal Medicine and Clinical Pharmacology. One of the inaugural “Specialists in Clinical Hypertension” and Fellows of the American Society of Hypertension, he contributed on five topics to  JNC VI, as well as to the “long version” of JNC 7. Some of his recent publications include meta-analyses of clinical trial results, putative risk factors for cardiovascular disease, cost-containment, pharmacoeconomics, and the assessment and enhancement of medication adherence. Dr. Elliott belongs to many professional societies interested in clinical pharmacology and in hypertension, including fellowship in the American Heart Association’s High Blood Pressure Council. He has lectured on five continents, participated in the review process for many journals, societies, study sections, and funding agencies, and served as editor or co-editor for many books, monographs, and symposia. Among his honors are 29 awards for teaching excellence.

 


Please wait ...

Back to Top